CP
SAGE

Caligan Partners’s Sage Therapeutics SAGE Stock Holding History

Caligan Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,052,538
Closed -$24.3M – 18
2025
Q1 		$24.3M Hold
3,052,538
– – 5.06% 6
2024
Q4 		$16.6M Buy
+3,052,538
New +$18.7M 4.2% 8

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Caligan Partners's SAGE Position: Q2 2025 in Review

Caligan Partners sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 3,052,538 shares — an estimated $24.3M sold.

Caligan Partners first reported a position in SAGE in Q4 2024 and held it in 2 quarters. The position peaked at $24.3M in Q1 2025. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Caligan Partners reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caligan Partners sold 3,052,538 Sage Therapeutics shares in Q2 2025, an estimated $24.3M.
  • Caligan Partners first reported a position in Sage Therapeutics in Q4 2024 and held it in 2 quarters.
  • Caligan Partners's Sage Therapeutics position peaked at $24.3M in Q1 2025.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Caligan Partners's 13F filing for Q2 2025, filed 14 Aug 2025.